Ethan Lovell, MBA
Senior Director of Investor Relations
Formerly Avidity Biosciences
Ethan Lovell is a biotechnology investor relations professional and former institutional investor with three decades of experience spanning biopharmaceutical equity research, portfolio management, corporate communications, and capital markets strategy. Most recently, Ethan served as Senior Director of Investor Relations at Avidity Biosciences, which was acquired by Novartis. Previously, Ethan served as Head of Investor Relations at Theravance Biopharma and Chief External Affairs & Communications Officer at Agenus.
Before his career in investor relations, Ethan spent more than two decades on Wall Street, including 12 years at Janus Henderson Investors as a healthcare analyst and portfolio manager, where he co-managed the $10 billion Global Life Sciences strategy. He also held investment positions at ClearBridge Investments, Saranac Capital Management, and Bear Stearns. Ethan combines experience in corporate communications and investor relations with firsthand knowledge of how institutional investors evaluate companies, allocate capital and manage risk.
He holds an MBA from Tulane University, an MA from the University of Denver, and a bachelor’s degree in chemistry from Bowdoin College.